Sign in
4

Changes in Ownership

Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-20-031054

CFO & Executive Vice President sold 29,113 shares at an average $73.33 ($2,134,885)

  • CFO & Executive Vice President acquired 26,721 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Sharp Shalini · CFO & Executive Vice President

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2020-05-18 Exercise or conversion : show line 1 in the form +19,593 $70.57 $1,382,678 122,929 D
2020-05-18 Sale : show line 2 in the form −19,593 $73.34 $1,436,951 103,336 D
2020-05-18 Sale : show line 3 in the form −2,392 $73.29 $175,310 100,944 D
2020-05-19 Exercise or conversion : show line 4 in the form +3,221 $48.43 $155,993 104,165 D
2020-05-19 Sale : show line 5 in the form −3,221 $73.32 $236,164 100,944 D
2020-05-19 Exercise or conversion : show line 6 in the form +3,907 $70.57 $275,717 104,851 D
2020-05-19 Sale : show line 7 in the form −3,907 $73.32 $286,461 101,556 D
Open-market sales · 29,113 sh · avg $73.33 · $2,134,885

Table II: Derivative

3 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2020-05-18 Exercise or conversion : show line 8 in the form Stock Option (Right to Buy) −19,593 $70.57 2026-06-01 19,593 4,407 D
2020-05-19 Exercise or conversion : show line 9 in the form Stock Option (Right to Buy) −3,221 $48.43 2028-03-01 3,221 31,779 D
2020-05-19 Exercise or conversion : show line 10 in the form Stock Option (Right to Buy) −3,907 $70.57 2026-06-01 3,907 500 D
Loading xslF345X03/doc4.xml…